Entera Bio (NASDAQ:ENTX) Issues Earnings Results

Posted by Geri Gentry on Aug 8th, 2026

Entera Bio (NASDAQ:ENTX – Get Free Report) announced its earnings results on Friday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06), Zacks reports.

Entera Bio Trading Up 1.8%

Shares of NASDAQ ENTX traded up $0.05 during mid-day trading on Friday, reaching $2.87. 244,911 shares of the company’s stock were exchanged, compared to its average volume of 4,887,891. The firm has a market capitalization of $141.46 million, a price-to-earnings ratio of -10.63 and a beta of 1.38. The business has a fifty day simple moving average of $1.85 and a 200 day simple moving average of $1.49. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ENTX. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.00.

View Our Latest Analysis on ENTX

Institutional Trading of Entera Bio

A number of institutional investors have recently modified their holdings of the company. Superstring Capital Management LP bought a new stake in Entera Bio in the 4th quarter valued at approximately $33,000. Citadel Advisors LLC lifted its position in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the last quarter. Jane Street Group LLC boosted its holdings in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

(Get Free Report)

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.